Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms

• Status: Recruiting
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase 3, randomized prospective study, double blind-double placebo, testing oral therapies APREPITANT versus HYDROXYZINE in patients followed for myeloproliferative neoplasms and suffering of persistent aquagenic pruritus.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Brest
• Treatments: Aprepitant; Fosaprepitant; Hydroxyzine

Criteria

Inclusion Criteria:

• Major patients with myeloproliferative neoplasms (polycythemia vera, essential thrombocythaemia or myelofibrosis)

• and treated with hydroxyurea, pipobroman, anagrelide, α2a pegylated interferon, ruxolitinib or bled for more than 6 months

• and suffering of persistent aquagenic pruritus

• and with a pruritus intensity on Analogic Visual Scale >5/10

• patients who gave their written consent for participation in the study

Exclusion Criteria:

• patients with a physical or psychological disability to sign the consent form

• patients with myeloproliferative neoplasms and suffering of aquagenic pruritus but only treated by aspirin

• patients already included in another therapeutic protocol

• patients with diffuse dermatological disease where pruritus may be present (psoriasis, atopic dermatitis, prurigo

• patients already on anti-anxiety and / or anti-depressant treatment

• patients with absolute contraindications to the use of Aprepitant or Hydroxyzine

• hypersensitivity to Aprepitant and / or Hydroxyzine or to any of their excipients

• lactose intolerance

• pregnant or lactating women